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Abstract
Background: The aim of this study was to evaluate the indications, results and complica-
tions of radiofrequency ablation (RFA) and transcatheter cryoablation (TCA) in neonates and 
infants with incessant drug-resistant supraventricular tachycardia (SVT).
Methods: Out of 225 patients who underwent RFA and TCA at our center between January 
2010 and February 2012, 5 patients under the age of 1 (4 male, 1 female) were evaluated. The 
indication for RFA/TCA was recurrent hemodynamically compromising drug-resistant SVT.
Results: Over a 2-year period, 6 ablation procedures were performed in 5 patients. Aver-
age patient age was 3.3 ± 3.9 months (12 days – 9.5 months); average patient weight was 
5.4 ± 2.2 kg (3.5–9 kg). One patient had ventricular septal defect, 1 had corrected transposition 
of great arteries, ventricular septal defect, right ventricular hypoplasia and pulmonary hyper-
tension, while 3 had only patent foramen ovale. Electrophysiology study showed 1 accessory 
pathway in each patient (right posteroseptal in 2, left posteroseptal in 2 and left lateral in 1). 
The pathway was manifest in 1 patient with Wolff-Parkinson-White syndrome (WPW) and 
concealed in the rest. Two of the concealed pathways had slow conduction time and decremental 
properties (the permanent form of junctional reciprocating tachycardia). Two patients under-
went TCA and 3 — RFA, with an acute success rate of 100%. In the first week after the procedure, 
the patient with the complex cardiac anomaly and WPW developed recurrence and underwent 
ablation again. Four of the procedures were carried out using an electroanatomic mapping system 
besides fluoroscopy. Average procedure time was 167 min (100–234); fluoroscopy time was 8.2 min 
(0.7–19.7). None of the patients developed major complications. After the average follow-up 
period of 6.5 months (3–18), all patients were symptom-free without medication. 
Conclusions: RFA and TCA can be performed successfully in neonates and infants with 
incessant medically refractory SVT. (Cardiol J 2013; 20, 3: 241–246)
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Introduction
Supraventricular tachycardia (SVT) is the 
most common type of tachyarrhythmia seen in 
pediatric patients, and accounts for more than 
90% of pediatric arrhythmias [1]. Symptoms vary 
according to age, duration of tachycardia and heart 
rate; neonates and infants can be admitted with 
congestive heart failure findings [1]. Although 
SVT in infants can be managed medically in most 
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cases and tends to spontaneously resolve within 
1 or 2 years, there is occasionally need for ablative 
therapy [1–3]. 
Radiofrequency ablation (RFA) has been de-
monstrated to be safe and effective in pediatric 
patients. In many centers, catheter ablation has 
become standard treatment of SVT in adolescents 
with symptomatic tachycardia [4, 5]. Although 
RFA has been used to treat SVT in younger pa-
tients and infants, it has generally been reserved 
for cases of life-threatening medically refractory 
tachyarrhythmia [3, 6, 7]. Due to low patient age 
and weight, concomitant congenital heart diseases 
and excessive application of radiofrequency (RF) 
energy, RFA has been linked to increased mor-
bidity and mortality [4, 8, 9]. Restrictions have 
also been placed on the use of RFA in smaller 
children since RFA lesions have been shown to 
have a progressing nature in animal studies [10], 
in addition to causing coronary ischemia and ve-
nous complications in infants [11]. In the recent 
years, use of transcatheter cryoablation (TCA) in 
children weighing less than 15 kg has been shown 
to be relatively complication-free [12]. This report 
summarizes our experience in using RFA and TCA 
to treat medically refractory SVT in neonates and 
infants. It is also the first study in our country to 
report on the use of catheter ablation in pediatric 
patients less than 1 year of age. 
Methods
From January 2010 to February 2012, 225 SVT 
patients underwent RFA and/or TCA at our center. 
Five patients were under 1 year of age (4 male, 
1 female). The indication for RFA/TCA in these 
patients was recurrent hemodynamically compro-
mising SVT that was resistant to medical manage-
ment, including amiodarone, esmolol, propafenon 
and a combination of class Ic and III agents. The 
following patient data were obtained from hospital 
records: age, gender, weight, the presence of stru-
ctural heart disease, SVT mechanism, accessory 
pathway location, catheter approach, SVT cycle 
length, number of RFA/TCA applications, total 
RFA/TCA time, average and maximum RFA/TCA 
temperatures, total procedure time, short-term 
success, complications, and follow-up.
Electrophysiological study
Informed consent was obtained from all pa-
rents prior to the procedures. Electrophysiology 
studies were carried out under general anaesthesia 
with the patients intubated. Hemodynamically 
compromised patients were observed in intensive 
care conditions, and those with left ventricular 
dysfunction were started on inotropic agents 
like dopamine, milrinone and adrenaline before 
the procedure began. In all patients, lines were 
inserted into the radial or femoral arteries and 
invasive blood pressure monitoring was done. Four 
procedures were performed using an electroanato-
mic mapping system (EnSite Velocity™, St. Jude 
Medical Inc., St. Paul, MN, USA) in addition to 
fluoroscopy, while the other 2 were performed in 
emergency conditions using only fluoroscopy. Elec-
trophysiologic catheters were inserted through the 
femoral and internal jugular veins. In 4 procedures, 
2 venous accesses (jugular and femoral vein) were 
obtained. The other 2 procedures, there was only 
1 venous access could be obtained and esophageal 
pacing catheter was used as the second catheter. 
All patients received 100 U/kg intravenous heparin 
during the ablation procedure with RFA. To map 
the tachycardia, we attempted catheter placement 
in the high right atrium, His bundle region, right 
ventricular apex and coronary sinus. To gain access 
to the left atrium, patent foramen ovale (PFO) was 
used. A standard atrial and ventricular protocol 
using single and double extrastimuli and burst 
pacing was used to induce SVT. In most cases the 
tachycardia was incessant and a complete atrial and 
ventricular protocol could not be performed before 
ablation. None of the patients required isoprenaline 
to sustain SVT. A diagnostic study was performed 
to determine the electrophysiological features of 
the accessory atrioventricular (AV) connections, 
the tachycardia mechanisms, and the location of 
the accessory pathways.
Catheter ablation techniques  
and post-procedure management
In all procedures, the atrial approach was used 
for ablation of the arrhythmogenic substrate. Ac-
cess for ablation in the right atrium was obtained 
through the femoral vein in 5 procedures and the 
jugular vein in 1 procedure. Access to the left 
atrium was through the PFO. 
Radiofrequency ablation. A 4-mm tip 5 F 
steerable quadripolar ablation catheter (St. Jude 
Medical Inc., St. Paul, MN, USA) was used for RFA. 
Once the ablation site was determined, 40–45 W 
RF energy was delivered for 25–47 s (for 1 appli-
cation) through the distal electrode of the ablation 
catheter. RF energy was delivered during sinus 
rhythm or SVT, or both depending on the stability 
of the catheter during each. Whenever application 
of energy terminated the SVT, or abolished ventri-
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cular pre-excitation, a second or more application 
(range, 2–4) was delivered at the same site with 
the same power. 
Cryoablation. An electroanatomic mapping 
system was used for cryoablation. The curve of the 
6-mm tip 7 F cryocatheter (FreezorTM, Medtronic 
Inc., Minneapolis, MN, USA) was not suitable for 
turning left after the foramen ovale and could only 
be used when the arrhythmogenic substrate was 
on the right. At first, cryomapping (for less than 
30 s and set to a minimum temperature of –30°) 
was performed to determine the area of the ear-
liest retrograde ventriculoatrial (VA) conduction 
during SVT. Then, cryoablation was applied to the 
area at a minimum temperature of –60° for 240 s. 
Whenever application of energy terminated the 
SVT, more was delivered to the same site for the 
same amount of time. 
After both RFA and TCA, a period of 30 min 
was allowed and ablation was considered successful 
if (1) no SVT could be induced at rest or with 
isoprenaline, and retrograde conduction showed 
decremental properties with a normal septal se-
quence; (2) SVT could not be induced and there 
was no retrograde conduction; (3) ventricular pre-
-excitation was abolished. At the end of the proce-
dure, all patients were returned to the intensive 
care unit and underwent continuous telemetry and 
Holter ECG monitoring for 48–72 h. Echocardio-
grams were taken immediately after the procedure. 
Aspirin (5 mg/kg) was given daily for 6 weeks for 
antiaggregation. A surface ECG, Holter ECG and 
an echocardiogram were done at follow-up. 
Results
The clinical features and cardiac statuses of 
the patients prior to ablation are summarized in 
Table 1. The average patient age was 3.3 ± 3.9 
months (12 days – 9.5 months); average weight 
— 5.4 ± 2.2 kg (3.5–9 kg). Surface ECGs of all 
patients showed reentrant SVT with narrow QRS. 
Two of the patients had structural heart anomalies 
while 3 had PFO. At admission since 4 patients 
were in cardiac shock, they were observed in 
the intensive care unit and intubated. Due to hy-
potension and metabolic acidosis, patients were 
started intravenous dopamine, adrenaline and 
milrinone. Patients had inotropic agents until the 
ablation procedure. Prior to the procedure, all 
patients received antiarrhythmic drugs including 
class Ic and III agents. Antiarrhythmic treatment 
responses had been monitored with the 24-h Holter 
and telemetric monitoring. Four of the 5 patients 
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showed no response to adenosine and/or cardiover-
sion. All patients were on intravenous amiodarone 
(5 mg/kg loading – 10 mg/kg/day maintenance). The 
duration of amiodarone treatment varied between 
48 h – 10 days (average 95.3 h). There were incessant 
SVT attacks 90% of day in 4 patients despite the me-
dical treatment. The remaning 1 patient (Patient 5) 
had recurrent STV attacks (about 1/3 of day) and 
arterial blood pressure had dropped 44/22 mm Hg 
during the attacks. In brief, electrophysiologic 
study and ablation were preferred since there were 
SVT attacks and there was request for inotropic 
agents despite the medical treatment for 4 patients, 
there were recurrent SVT attacks and clinical de-
terioration for 1 patient.
Electrophysiological study  
and ablation procedure characteristics
Table 2 summarizes the electrophysiologic 
study findings of patients. Two patients had a right 
posteroseptal accessory pathway, 2 — left poste-
roseptal and 1 — left lateral. There were 4 con-
cealed and 1 manifest accessory pathways. Two of 
the concealed pathways had slow conduction time 
and decremental properties (the permanent form 
of junctional reciprocating tachycardia — PJRT). 
The tachycardia cycle length was 284 ± 38 ms. 
Except one (Patient 5), all patients had incessant 
tachycardia during the electrophysiology study.
The ablation data are summarized in Table 2. 
Patients underwent a total of 6 successful proce-
dures. The patient with complex congenital heart 
disease and Wolff-Parkinson-White syndrome 
(WPW) (Patient 5) reverted to sinus rhythm after 
a successful ablation and was kept in the intensive 
care unit for 48 h. However, the patient had another 
SVT attack 7 days after the procedure and unde-
rwent a second ablation procedure. Three patients 
with left-sided accessory pathways underwent RFA 
in the left atrium via PFO, while 2 patients with 
PJRT underwent TCA. An average of 3 ± 0.8 RFA 
lesions were placed in total, with an average dura-
tion of 98 ± 38 s. The average total time of RFA 
procedures (measured from the time the patient 
entered the laboratory until exit time) was 161 ± 
± 59 min, while the average fluoroscopy time was 
11.1 ± 7 min. An average of 7 TCA applications was 
performed in 2 patients with PJRT, with an average 
ablation time of 1750 ± 240 s. The average total 
TCA procedure time (measured from the time the 
patient entered the laboratory until exit time) was 
180 min, while the average fluoroscopy time was 
2.6 min. Four procedures were carried out using 
an electroanatomic mapping system (average flu- Ta
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oroscopy time 4 ± 2.4 min), while 2 procedures 
were carried out in emergency circumstances 
relying on fluoroscopy (average fluoroscopy time 
16.8 ± 4.1 min). 
Following catheter ablation, all patients were 
evaluated using ECG, telemetry, Holter ECG and 
echocardiography. Patients with left ventricular 
dysfunction recovered completely and were gra-
dually taken off inotropic agents. Heparin admi-
nistration was continued for 24 h in patients with 
left-sided lesions. All patients were on aspirin 
(5 mg/kg/day, single dose) for 6 weeks. Echocardio-
graphy showed that Patient 3 developed moderate 
tricuspid valve insufficiency and hyperechogenicity 
in the annulus next to the valve septal leaflet follo-
wing the procedure. As edema or thrombosis could 
not be excluded, the patient received heparin for 
48 more hours and the findings had completely 
regressed by the time of the last examination. 
Average hospitalization time (pre-procedure, in-
tensive care and hospital stay) was 12 ± 4 (range: 
6–17) days. Echocardiographic evaluation of all 
patients prior to their release showed normal left 
ventricular function. After an average follow-up 
period of 6.5 (range: 3–18) months, all patients 
were symptom free without medication. 
Discussion
This report demonstrates that RFA and/or 
TCA can be a reliable and effective option in cases 
where neonates or infants have hemodynamically 
compromising SVT that persists despite aggressive 
medical treatment. The natural course of SVT in 
most neonates and infants includes resolution of 
the tachycardia by 1 year of age [1, 2]. Normally, 
pharmacologic therapy is used to suppress the 
tachycardia until spontaneous resolution occurs, 
but in some infants SVT cannot be controlled 
with a traditional first-line agent such as digoxin 
or propranolol. If these fail, other antiarrhythmic 
agents like amiodarone, flecainide, propafenone and 
sotalol are added or used in combination [1, 2, 13]. 
If SVT persists despite conventional pharmacologic 
therapy and is complicated by ventricular dysfun-
ction, catheter ablation can be used for definitive 
treatment [2–7]. 
Although the number of studies focusing on 
the use of RFA to manage SVT in neonates and 
infants increases by the day, the topic remains 
controversial [2–8]. According to the Pediatric 
Radiofrequency Ablation (RFCA) registry data from 
1991–1997, body weight of less than 15 kg poses 
a significant risk of complications during RFA, 
including AV block, cardiac perforation and even 
death [5]. However, a 2001 subgroup analysis of 
patients younger than 18 month-old (all of whom 
weighed under 15 kg) showed no increased pro-
cedural risk relative to the rest of the database 
population [6]. This controversy was highlighted 
by the recently published North American Society 
of Pacing and Electrophysiology (NASPE) expert 
consensus conference in which the use of RFA in 
children younger than 5 years of age with SVT 
refractory to drug therapy, including sotalol and 
amiodarone, was believed to represent a class IIb 
indication [14]. Lastly, Aiyagari et al. [3] reported 
on the risks and results of RFA use in children 
under 15 kg and between 15 and 20 kg, stating that 
RFA use in small children was safe and effective. 
The main reason for contradictions is that there 
are really limited number of RFA indications in 
neonates and infants with SVT and thus less 
experiences with these situations. Use of RFA 
in small children can lead to cardiac perforation, 
pericardial effusion, pneumothorax, coronary ar-
tery injury, AV block, and death. Additionally, the 
potential progressive nature of RFA lesions can also 
increase complication rates in younger patients 
[6–11]. In order to minimize or altogether avoid 
these complications, RFA should be performed by 
an experienced pediatric electrophysiologist who 
can reduce risk by varying power, temperature, 
application duration and number of attempts de-
pending on the patient’s size [6, 7]. In our study, 
catheter ablation was carried out by an experienced 
pediatric electrophysiologist, and no major compli-
cations were seen. RF energy was delivered via 
a 4-mm tip catheter, application duration was 30 s 
on average and was always preceeded by a 3–5 s 
test application. Although some of our patients 
were only 12 day-old and weighed 3.5 kg, no major 
complications developed. This is attributable to 
all patients being closely monitored prior to and 
following the procedure (blood pressure monitoring 
via an artery catheter, constant supervision by 
a pediatric cardiologist, periodical ECG and ECHO 
follow-up) and good management of their inotropic 
support and ventilation needs. 
The complications caused by RFA in neonates 
and infants bring to mind the alternative energy 
sources used in cryoablation. TCA has been shown 
to be effective and reliable in pediatric patients with 
AV nodal reentrant tachycardia or SVT with acces-
sory pathways [15, 16]. However, until 2011, stu-
dies of TCA use in neonates and infants remained 
very limited [17, 18]. The only publication on this 
topic is an international multicenter retrospective 
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study (Members of the Pediatric and Congenital 
Electrophysiology Society) that included 61 pa-
tients under 5 years of age and/or weighing less 
than 15 kg [12]. Those patients who had to undergo 
RFA due to failed TCA developed complications, 
while those who only underwent TCA had none. 
The study also found that TCA had lower success 
rates and higher recurrence rates. In our study, 
TCA was used in two patients with PJRT and no 
recurrences had been seen by the end of the follow-
-up period. Among the advantages of cryoablation 
are greater catheter stability, lesion reversibility, 
sharply demarcated lesions that preserve tissue 
integrity, and a  low risk of thrombosis [15, 16]. 
Disadvantages include a  larger catheter size and 
less catheter steerability, which may limit its use 
in neonates and infants. In our opinion, production 
of catheters of smaller size that will allow for more 
manipulation would lead to cryoablation becoming 
the preferred choice. 
Another important point of our study is the 
use of an electroanatomic mapping system, with 
the exception of emergency cases. The EnSite 
system guidance can be safely and effectively 
used as the primary catheter visualization tool 
during catheter ablation. Besides its advantage 
in 3D mapping, this system was used to reduce 
fluoroscopic exposure [19, 20]. In the pediatric 
ablation registry, the average fluoroscopy time 
for ablation of SVT is 40 min [21]. With newborns 
and infants, this time can extend to up to 194 min 
[6, 7, 17]. When we used the 3D mapping system, 
the average time of fluoroscopy was only 4 min. 
Mapping systems present an effective alternative 
to leaving younger patients exposed to radiation 
for long periods of time. 
Conclusions
Catheter ablation in neonates and infants shou-
ld be reserved for life-threatening arrhythmias that 
persist after multiple failed attempts at medical 
management, including various combination thera-
pies. RFA should be performed by an experienced 
pediatric electrophysiologist who can use various 
strategies to reduce complication risks based on 
the patient’s size. TCA can be a safe and effective 
option to RFA in selected patients. 
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